Our observation that overexpression of miR-125a-3p in a cell line of the basal-like breast cancer subtype resulted in high expression of ErbB2 prompted us to further explore whether modulation with miR-125a-3p may sensitize these cells to the highly effective anti-HER2 therapies. The gene discussed is ERBB2; the disease is breast carcinoma.